Pharma News

Revenue for Cetirizine hydrochloride is expected to have a CAGR of -31.96% through 2027

Cetirizine hydrochloride is a Small Molecule owned by UCB, and is involved in 5 clinical trials, which were completed.

Cetirizine, a human metabolite of hydroxyzine, is a potent and selective antagonist of peripheral H1-receptors. Cetirizine competes with histamine for binding at H1-receptor sites on the effector cell surface and occupies the histamine receptor sites, resulting in suppression of histaminic edema, flare and pruritus.

The revenue for Cetirizine hydrochloride is expected to reach a total of $151m through 2027. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cetirizine hydrochloride NPV Report.

Cetirizine hydrochloride is currently owned by UCB. GSK is the other company associated in development or marketing of Cetirizine hydrochloride.

Cetirizine hydrochloride Overview

Cetirizine hydrochloride (Zyrtec, Zirtec, Zyrtec P, Benaday, ZyrtecSet, Benadryl, Reactine) is an antihistamine and an anti-allergic agent. It is formulated as tablets, film coated tablets, chewable tablets, capsules, dry syrup, drops and solution for oral route of administration. It is indicated for the relief of symptoms associated with seasonal allergic rhinitis due to allergens such as ragweed, grass and tree pollens in adults and children 2 years of age and older, symptoms treated effectively include sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of the eyes. It is also indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in adults and children 6 months of age and older. It is further indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. It is further indicated for the treatment of nasal congestion.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020.
The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – Cetirizine hydrochloride

Report Segments
Drug Name
Administration Pathway
Therapeutic Areas
  • Dermatology
  • Immunology
  • Ophthalmology
  • Respiratory
Key Companies
Highest Development Stage

Source link
#Revenue #Cetirizine #hydrochloride #expected #CAGR

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *